AMY S. BROIDRICK

CIK 1822917 · President/CSO · last filed 2022-08-04

AMY S. BROIDRICK is a President/CSO who has filed 6 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for QLGN, was dated Aug 4, 2022. Across all open-market trades the lifetime net is +$27.7K, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

6

Lifetime Open-Market Net

$27.7K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Qualigen Therapeutics, Inc. (QLGN) Delisted President/CSO 34,500 $3.21 $110.7K $27.7K 6 2022-08-04

Recent Filings

6 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2022-08-04 Qualigen Therapeutics, Inc. (QLGN) Delisted Grant (A) $0 EDGAR
2022-06-15 Qualigen Therapeutics, Inc. (QLGN) Delisted Buy (P) +30,000 $18.6K EDGAR
2021-12-10 Qualigen Therapeutics, Inc. (QLGN) Delisted Grant (A) $0 EDGAR
2021-04-26 Qualigen Therapeutics, Inc. (QLGN) Delisted Buy (P) +4,500 $9.1K EDGAR
2020-12-29 Qualigen Therapeutics, Inc. (QLGN) Delisted Grant (A) $0 EDGAR
2020-08-28 Qualigen Therapeutics, Inc. (QLGN) Delisted Grant (A) $0 EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.